Get access

Low dose cytarabine monotherapy for myelodysplastic syndromes

  • Protocol
  • Intervention

Authors

  • Kathrin Bauer,

    Corresponding author
    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    • Kathrin Bauer, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. kathrin.bauer@uk-koeln.de.

    Search for more papers by this author
  • Franz Hutzschenreuter,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Nicole Skoetz,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Ina Monsef,

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Karl-Anton Kreuzer,

    1. University Hospital of Cologne, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author
  • Andreas Engert

    1. University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The main objective of this systematic review is to evaluate the efficacy and safety of low dose cytarabine for patients with MDS.

Get access to the full text of this article